No Data
*ST Jingfeng (000908.SZ): Shareholder Ye Xiangwu's shareholding period is more than half over, with a total shareholding of 1.0448 million shares.
On August 12th, *ST Jingfeng (000908.SZ) announced that the company recently received a notice from shareholder Mr. Ye Xiangwu regarding the shareholding plan of Hunan Jingfeng Pharmaceutical, which has passed the halfway point of its implementation. As of the date of the announcement, Mr. Ye Xiangwu has accumulated 1.0448 million shares of the company's stock through centralized bidding trading on the Shenzhen Stock Exchange system, accounting for 0.12% of the total share capital of the company. The total amount of shareholding reached 2.0029 million yuan (excluding transaction fees), which has reached the lower limit of this shareholding plan.
August 9th A-share lightning rod | Liuzhou Chemical Industry: China Construction Bank Guangxi Branch and China Construction Bank Financial Leasing intend to reduce their total shareholding by no more than 3%; *Guizhou Changzheng Tiancheng Holding: The sto
Beijing Jingxi Culture & Tourism shareholder Qingdao Haifa plans to reduce its shareholding by no more than 3%; Liuzhou Chemical Industry shareholder China Construction Bank Guangxi Branch and Jianxin Golden Lease plan to reduce their shareholding by no more than 3%; The stocks of Guizhou Changzheng Tiancheng Holding, ST, will be delisted and removed from the market on August 15; ST Dong Shi claimed that the China Securities Regulatory Commission has decided to file a case against the actual controller Xu Xiong; ST Jingfeng stated that the recruitment of investors for restructuring has been postponed.
ST Jingfeng (000908.SZ): Recruitment of restructuring investors postponed.
On August 8, Gelonhui reported that special treat Hunan Jingfeng Pharmaceutical (stock code: 000908.SZ) announced that in order to speed up the company's pre-restructuring work, the interim administrator released a notice to recruit potential investors on the national enterprise bankruptcy restructuring case information network on August 1, 2024. On August 2, 2024, the company released a notice on the designated information disclosure media to publicly recruit restructuring investors, and openly recruited and selected pre-restructuring investors from the society. As of August 8, 2024, some potential investors indicated that the time to prepare materials was tight and internal approval had not yet been completed.
* ST Jingfeng (000908.SZ): There may be a risk of a sharp drop in stock price after a significant increase.
*ST Jingfeng (000908.SZ) announced that the company's stocks will be suspended from trading on August 5, 6, and 7, 2024...
ST Jingfeng (000908.SZ): Stocks trade with serious abnormal fluctuations, without disclosing any significant information.
On July 17th, Gelunhui reported that the stock (*ST Jingfeng, stock code: 000908) of Jingfeng has deviated from the closing price for the past three consecutive trading days between July 15th and July 17th of 2024, with a cumulative increase of 17.01%. According to the relevant provisions of the Shenzhen Stock Exchange Trading Rules, it belongs to abnormal fluctuations in stock trading; at the same time, the company's stock has appeared abnormal fluctuations in the same direction in 4 out of the last ten consecutive trading days, which constitutes serious abnormal fluctuations in stock trading. The board of directors confirmed that the company currently has no basis for trading.
Hunan Jingfeng Pharmaceutical: 2024 Interim Performance Forecast
Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five YearsNo Data
